COVID-19 and Rheumatology
Rural patients with AIRDs have 24% higher post-COVID mortality risk vs urban population
Patients with autoimmune or inflammatory rheumatic diseases living in rural areas demonstrate a 24% higher mortality risk after SARS-CoV-2 infection vs. those in urban areas, according to data published in Arthritis Care & Research.
No increased autoimmune risk after omicron, delta COVID-19 in boosted patients
New diagnoses of autoimmune diseases were not overall more likely among vaccinated patients infected with omicron or delta variants of COVID-19, compared with those not infected, according to data published in JAMA Network Open.
‘Very little evidence’ that COVID-19 alters course of rheumatic, autoimmune diseases
SAN DIEGO — Although a flood of COVID-19 and long COVID research continues to emerge, concerns may be limited for rheumatologists, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
Risk for myalgic encephalomyelitis/chronic fatigue syndrome no greater after COVID-19
COVID-19 does not increase patients’ risk for developing myalgic encephalomyelitis/chronic fatigue syndrome during the 1-year period post infection, according to a registry study published in JAMA Network Open.
Lupus risk higher after mRNA vaccination against COVID-19
Patients who received an mRNA COVID-19 vaccine demonstrated a 1.16-fold higher long-term risk for systemic lupus erythematosus, while a booster was linked to higher risk for psoriasis and rheumatoid arthritis, according to data.
Rheumatology perspective: Will NASEM’s new long COVID definition aid diagnosis, treatment?
On June 11, the National Academies of Sciences, Engineering and Medicine issued the result of their lengthy deliberations to develop a consensus definition for long COVID.
Nearly 30% of patients with autoimmune disease report long COVID after infection
Among patients with systemic autoimmune disease in a large, real-world cohort, 29.8% reported long COVID, with frequent impacts to quality of life, following infection, according to data published in The Journal of Rheumatology.
Paxlovid, though safe, shows no benefit in long COVID treatment
A 15-day course of Paxlovid demonstrated no significant benefit for patients with post-acute sequelae of SARS-CoV-2 infection, according to data published in JAMA Internal Medicine.
‘Common and unique immune features’ in long COVID may lead researchers to treatments
Patients with long COVID symptoms demonstrate elevated levels of several inflammatory molecules — findings that could have important implications in both rheumatology and the search for a potential treatment for long COVID.
Third COVID-19 vaccine dose beneficial for most immunocompromised patients
A third dose of COVID-19 vaccine can boost serological and T-cell response among most patients who are immunocompromised, according to data published in The Lancet Rheumatology.